What biomarker testing is recommended for locally advanced Colorectal Cancer

Biomarker Testing for Locally Advanced Colorectal Cancer

Great question. Let me explain what testing is recommended and why it matters for your care.

What "Locally Advanced" Means

Locally advanced colorectal cancer means the cancer has grown deeper into the bowel wall and/or spread to nearby lymph nodes, but hasn't yet spread to distant organs (like the liver or lungs). This is typically Stage III disease.

Recommended Biomarker Testing

According to NCCN Guidelines for Colon Cancer, here are the key tests your oncology team should perform:

1. Mismatch Repair (MMR) or Microsatellite Instability (MSI) Testing ✓ UNIVERSAL

This is recommended for all newly diagnosed patients with colon cancer:

• What it measures: Whether your tumor has defects in DNA repair machinery
• Why it matters:
  • Helps identify Lynch syndrome (hereditary cancer risk)
  • Guides immunotherapy decisions if your cancer progresses
  • Stage II MSI-high tumors have better prognosis and may not need chemotherapy
• Testing method: Immunohistochemistry (IHC) or PCR-based testing on tumor tissue

2. KRAS and NRAS Mutation Testing ✓ RECOMMENDED FOR METASTATIC DISEASE

While primarily recommended for metastatic (Stage IV) disease, testing may be considered:

• What it measures: Mutations in genes that control cell growth
• Why it matters:
  • Predicts response to targeted therapies (cetuximab, panitumumab)
  • Patients with KRAS or NRAS mutations should NOT receive these drugs
  • Important if your cancer progresses later
• Testing method: Next-generation sequencing (NGS) preferred, or individual gene testing

3. BRAF V600E Mutation Testing ✓ RECOMMENDED FOR METASTATIC DISEASE

Similar to KRAS/NRAS, this is primarily for advanced disease but may be ordered:

• What it measures: A specific mutation affecting cell signaling
• Why it matters:
  • Indicates poor response to certain targeted therapies
  • Requires combination treatment if present
  • Associated with worse prognosis

4. HER2 Amplification Testing ✓ CONSIDER FOR ADVANCED DISEASE

May be recommended if your cancer progresses:

• What it measures: Extra copies of the HER2 gene
• Why it matters: Opens up targeted therapy options (trastuzumab-based treatments)

5. NTRK Fusion Testing ✓ CONSIDER

Part of comprehensive NGS panels:

• What it measures: Abnormal joining of NTRK genes
• Why it matters: Rare but actionable—can be treated with targeted drugs (larotrectinib, entrectinib)

---

Testing Approach: What's Best?

According to NCCN Guidelines, next-generation sequencing (NGS) is preferred because it:

• Tests multiple genes at once
• Can detect rare, actionable mutations
• Can be done on tissue or blood samples
• Is more efficient than individual gene testing

Important note: Testing should be performed in CLIA-certified laboratories (Clinical Laboratory Improvement Amendments) to ensure quality and accuracy.

---

Key Timing Considerations

• MMR/MSI testing: Should be done at diagnosis for all patients
• KRAS/NRAS/BRAF testing: Primarily important if your cancer becomes metastatic, but some centers test upfront
• Repeat testing: Generally NOT recommended after standard chemotherapy, as mutations rarely change. However, repeat testing may be considered after targeted therapies to guide future treatment decisions.

---

Why This Matters for Your Care

These biomarkers help your oncology team:

1. Predict prognosis (how the cancer may behave)
2. Guide treatment decisions (which therapies will work best)
3. Identify hereditary risk (whether family members should be screened)
4. Plan for the future (what to watch for if cancer progresses)

---

Questions to Ask Your Oncology Team

1. "Has my tumor been tested for MMR/MSI status?" (This should be done for all patients)
2. "Should we do comprehensive NGS testing now, or wait to see if my cancer progresses?"
3. "Which laboratory will be performing these tests, and are they CLIA-certified?"
4. "How will these results change my treatment plan?"
5. "If my cancer progresses later, will we need to repeat any of these tests?"
6. "Are there any hereditary cancer syndromes I should be screened for based on my results?"

---

Sources

This information is based on:

• NCCN Guidelines for Colon Cancer (Version 5.2025) - specifically the "Principles of Pathologic and Molecular Review" section
• NCCN Guidelines for Rectal Cancer (Version 4.2025) - molecular testing recommendations

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.